epocrates logo
epocrates logo
epocrates logo
  • 0

Interaction Check

epocrates logo

Sign in to access our clinical decision support tools

Sign in Create Account

Selected Drugs Clear All

  • remove ArmonAir Digihaler
    fluticasone propionate inhaled
  • remove Bactrim DS
    sulfamethoxazole/ trimethoprim
  • remove Kesimpta
    ofatumumab

multicheck MultiCheck Results - 2 Interactions

Smiley face Smiley face

Monitor/Modify Tx

Smiley face Smiley face Bactrim DS (sulfamethoxazole/ trimethoprim) + Kesimpta (ofatumumab)

Monitor/Modify Tx


trimethoprim + ofatumumab

monitor CBC; myelosuppression risk may be lower w/ ofatumumab doses used for MS: combo may incr. risk of myelosuppression (additive effects)

Caution Advised

Smiley face Smiley face ArmonAir Digihaler (fluticasone propionate inhaled) + Kesimpta (ofatumumab)

Caution Advised


fluticasone propionate + ofatumumab

caution advised: combo may incr. risk of serious infection (additive effects)

Additional Considerations

Smiley face Smiley face ofatumumab in Kesimpta

myelosuppression associated with higher, more frequent doses used for cancer chemotherapy, lower risk with MS doses

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information